Endocrinologic and Metabolic Drugs Advisory Committee Hilton Hotel, Washington DC-Silver Spring Silver Spring, Maryland April 2, 2009

Meeting Roster

ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Kenneth D. Burman, M.D.

(Chair) Chief, Endocrine Section Washington Hospital Center Washington, District of Columbia

Katherine M. Flegal, Ph.D.

Senior Research Scientist Distinguished Consultant National Center for Health Statistics Centers for Disease Control and Prevention Hyattsville, Maryland

Michael A. Proschan, Ph.D.

Mathematical Statistician Biostatistics Research Branch National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH) Bethesda, Maryland

Eric I. Felner, M.D.

Emory University School of Medicine Department of Pediatrics Division of Endocrinology Atlanta, Georgia

Jessica W. Henderson, Ph.D.

Associate Professor Division of Health and Physical Education Western Oregon University Monmouth, Oregon

ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS, INDUSTRY REPRESENTATIVE (Non-Voting)

Enrico P. Veltri, MD

Group Vice President Global Clinical Development Cardiovascular and Metabolic Diseases Schering-Plough Research Institute Kenilworth, New Jersey

DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE MEMBER (Voting)

Timothy S. Lesar, Pharm.D.

Director of Pharmacy Albany Medical Center Albany, New York

Endocrinologic and Metabolic Drugs Advisory Committee Hilton Hotel, Washington DC-Silver Spring Silver Spring, Maryland April 2, 2009

Meeting Roster

CENTER FOR DRUG EVALUATION AND RESEARCH TEMPORARY VOTING MEMBERS (Voting)

Lynne L. Levitsky, M.D.

Chief, Pediatric Endocrine Unit Massachusetts General Hospital Boston, Massachusetts

John R. Teerlink, M.D.

Associate Professor of Medicine, UCSF Director, Heart Failure Clinic, SFVAMC Director, Clinical Echocardiography, SFVAMC San Francisco VA Medical Center San Francisco, California

Peter J. Savage, M.D.

Senior Advisor to the Director Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD), NIDDK National Institutes of Health (NIH) Bethesda, Maryland

Michael R. Tuttle, M.D.

Endocrine Service Memorial Sloan Kettering Cancer Center New York, New York

FDA PARTICIPANTS (Non-Voting)

Curtis Rosebraugh, M.D., M.P.H.

Director Office of Drug Evaluation II Center for Drug Evaluation and Research (CDER) Food and Drug Administration (FDA)

Hylton Joffe, M.D. M.M.Sc

Diabetes Clinical Team Leader Division of Metabolism and Endocrinology Products CDER, FDA

Rebecca W. Killion

Patient Representative Bowie, Maryland

Kathleen L. Wyne, M.D., Ph.D.

Director of Clinical Research, Diabetes Research Center The Methodist Hospital Research Institute Assistant Professor, Department of Medicine Weill Cornell Medical College The Methodist Hospital Houston, Texas

Marvin A. Konstam, M.D.

Chief Physician Executive, The Cardiovascular Center Tufts Medical Center Professor of Medicine Tufts University School of Medicine

Mary H. Parks, M.D.

Director Division of Metabolism and Endocrinology Products CDER, FDA

Anthony Parola, Ph.D

Pharmacology/Toxicology Reviewer Division of Metabolism and Endocrinology Products CDER, FDA

Endocrinologic and Metabolic Drugs Advisory Committee Hilton Hotel, Washington DC-Silver Spring Silver Spring, Maryland April 2, 2009

Meeting Roster

Karen Mahoney, M.D.

Clinical Reviewer Division of Metabolism and Endocrinology Products CDER, FDA